Boston Scientific Announces Results for First Quarter 2024

Boston Scientific (BSX) PT Raised to $77 at Oppenheimer

Oppenheimer analyst Steven Lichtman raised the price target on Boston Scientific (NYSE: BSX) to $77.00 (from $68.00) while maintaining a Outperform rating.

The analyst comments "BSX delivered 1Q24 sales meaningfully ahead of the Street (13% organic y/y). EPS was also beat ($0.56 versus our/Street's... More

Boston Scientific (BSX) PT Raised to $82 at RBC Capital

RBC Capital analyst Shagun Singh raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $78.00) while maintaining a Outperform rating.

The analyst comments "BSX delivered solid beat with an upside surprise of ~5% and ~10% on sales and EPS, respectively. Given this momentum (+660bps... More

Boston Scientific (BSX) PT Raised to $82 at Wells Fargo

Wells Fargo analyst Lawrence Biegelsen raised the price target on Boston Scientific (NYSE: BSX) to $82.00 (from $72.00) while maintaining a Overweight rating.

The analyst comments "Today (4/24), BSX reported Q1 rev/EPS ahead of Street and raised 2024 rev guidance by 250bps at the mdpt to 10-12%.... More

Boston Scientific (BSX) PT Raised to $80 at BTIG

BTIG analyst Marie Thibault raised the price target on Boston Scientific (NYSE: BSX) to $80.00 (from $74.00) while maintaining a Buy rating.

The analyst comments "After a record-setting 2023, Boston Scientific is starting 2024 at an even faster pace. BSX reported Q1 revenue of $3.856B (+13.8% y/y rep., +13.1% org.) and adj. EPS of $0.56 (consensus $3.684B and $0.51), well above its guidance... More

Boston Scientific (BSX) pipeline strength fuels quarterly earnings beat

Boston Scientific (NYSE: BSX) reported a significant earnings and revenue beat for the first quarter of 2024, exceeding analyst expectations and providing an optimistic outlook for the future. The company's shares rose by 2.7% as the market responded positively to the news.

The medical device maker announced an adjusted EPS of $0.56, surpassing the consensus estimate of $0.51. Revenue for the quarter was also higher than anticipated, coming in at $3.86 billion against the expected $3.68 billion. These figures... More

Boston Scientific (BSX) Tops Q1 EPS by 5c; Guides Above Views

Boston Scientific (NYSE: BSX) reported Q1 EPS of $0.56, $0.05 better than the analyst estimate of $0.51. Revenue for the quarter came in at $3.86 billion versus the consensus estimate of $3.68 billion.

GUIDANCE:

Boston Scientific sees Q2 2024 EPS of $0.57-$0.59, versus the consensus of... More